PARP1 promotes EGFR-TKI drug-resistance via PI3K/AKT pathway in non-small-cell lung cancer. Xu X, Liu Y, Gong Q, Ma L, et al. Cancer Chemother Pharmacol 2024 Apr 12. doi: 10.1007/s00280-024-04668.

Read + Share

Amedeo Smart

Independent Medical Education

Xu X, Liu Y, Gong Q, Ma L, et al. PARP1 promotes EGFR-TKI drug-resistance via PI3K/AKT pathway in non-small-cell lung cancer. Cancer Chemother Pharmacol 2024 Apr 12. doi: 10.1007/s00280-024-04668.
PMID: 38609654